The four as associated with pathological Parkinson disease gamblers: Anxiety, anger, age, and agonists

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 1, 2007, Pages 161-167

  Shapiro, Michael A ^a   Chang, Yu Ling ^b   Munson, Sarah K ^a   Jacobson IV, Charles E ^a   Rodriguez, Ramon L ^a   Skidmore, Frank M ^a   Okun, Michael S ^a   Fernandez, Hubert H ^a,c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c NONE   (United States)

Author keywords

Anxiety; Compulsive behavior; Dopamine agonist; Gambling; Parkinson

Indexed keywords

AMANTADINE; ANXIOLYTIC AGENT; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGE; AGED; ANAMNESIS; ANGER; ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; BEHAVIOR; CONFUSION; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DISTRESS SYNDROME; ENVIRONMENTAL FACTOR; FAMILY HISTORY; FEMALE; FREQUENCY ANALYSIS; HEALTH SURVEY; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; POSTAL MAIL; UNITED STATES;

EID: 34249069822     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2007.3.1.161     Document Type: Article

References (29)

1. Alexander GE, Crutcher MD, DeLong MR. 1990. Basal ganglia-thalamo-cortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res, 85:119-46.
2. Avanzi M, Uber E, Bonfa F. 2004. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease. Neurol Sci, 25:98-101.
3. Bergh C, Eklund T, Sodersten P, et al. 1997. Altered dopamine function in pathological gambling. Psychol Med, 27:473-5.
4. Clarke CE, Guttman M. 2002. Dopamine agonist monotherapy in Parkinson's disease. Lancet, 360:1767-9.
5. Comings DE, Rosenthal RJ, Lesieur HR, et al. 1996. A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics, 6:223-34.
6. Destee A. Therapeutic strategies for Parkinson's disease [Article in French]. 2005. Rev Prat, 55:723-32.
7. Dodd ML, Klos KJ, Bower JTH, et al. 2005. Pathological gambling caused by drugs used to treat Parkinson's disease. Arch Neurol, 62:1-5.
8. Driver-Dunkley E, Samanta J, Stacy M. 2003. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology, 61:422-3.
9. Frank MJ, Seeberger LC, O'Reilly RC. 2004. By carrot or stick: Cognitive reinforcement learning in Parkinsonism. Science, 306:1940-3.
10. Giovannoni G, O'Sullivan JD, Manson AJ, et al. 2000. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. JNNP, 68:123-8.
11. Gschwandtner U, Aston J, Renaud S, et al. 2001. Pathologic gambling in patients with Parkinson's Disease. Clin Neuropharmacol, 24:170-2.
12. Hughes AJ, Ben-Schlomo Y, Daniel Se, et al. 1992. What features improve the accuracy of clinical diagnosis in Parkinson's disease. Neurology, 42:1142-6.
13. Jankovic J. 2005. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord, 20: Suppl 11:S11-16.
14. Kurlan R. 2004. Disabling repetitive behaviors in Parkinson's disease. Mov Disord, 19:433-7.
15. Levens S, Dyer AM, Zubritsky C, et al. 2005. Gambling among older, primary-care patients: an important public health concern. Am J Geriatr Psychiatry, 13:69-76.
16. Martins SS, Tavares H, da Silva Lobo DS, et al. 2004. Pathological gambling, gender, and risk-taking behaviors. Addict Behav, 29:1231-5.
17. Meiran N, Friedman G, Yehene E. 2004. Parkinson's disease is associated with goal-setting deficits during task switching. Brain Cogn, 54:260-2.
18. Molina JA, Sainz-Artiga JM, Fraile A, et al. 2000. Pathologic gambling in Parkinson's Disease: A behavioral manifestation of pharmacologic treatment? Mov Disord, 15:869-72.
19. Moller JC, Korner Y, Dodel RC, et al. 2005. Pharmacotherapy of Parkinson's disease in Germany. J Neurol, 252:926-35.
20. Noble EP. 2000. The DRD2 gene in psychiatric and neurological disorders and its phenotypes. Pharmacogenomics, 1:309-33.
21. Petry NM, Stinson FS, Grant BF. 2005. Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry, 66:564-74.
22. Pietrzak RH, Molina CA, Ladd GT, et al. 2005. Health and psychosocial. correlates of disordered gambling in older adults. Am J Geriatr Psychiatry, 13:510-19.
23. Samii A, Nutt JG, Ransom BR. 2004. Parkinson's disease. Lancet, 363:1783-93.
24. Seedat S, Kesler S, Niehaus DJH, et al. 2000. Pathological gambling behaviour: Emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety, 11:185-6.
25. Shizgal P and Arvanitogiannis A. 2003. Gambling on dopamine. Science, 299:1856-v8.
26. Sokoloff P, Giros B, Martres MP, et al. 1990. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature, 347:146-51.
27. Swainson R, Rogers RD, Sahakian BJ, et al. 2000. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia, 38:596-612.
28. Unwin BK, Davis MK, De Leeuw JB. 2000. Pathologic gambling. Am Fam Physician, 61:741-9.
29. Zald DH, Boileau I, El-Dearedy W, et al. 2004. Dopamine transmission in the human striatum during monetary reward tasks. J Neurosci. 24:4105-12.